
## **NICE Prioritisation Board**



## Omitting prioritisation process

- Medicines as per the 2024 Department of Health and Social Care voluntary scheme for branded medicines, pricing, access and growth, except there is a clear rationale not to omit the prioritisation process. Where routing decision is required for technology appraisal or highly specialised technology, it will go straight to prioritisation stage 2
- Special referrals by the Secretary of State to assess health/ medical technologies with a mandate
- Selected interventional procedures, except where ratification or further routing decision from the prioritisation board is required (go straight to prioritisation stage 2)
- Updates of existing guidance, except where ratification, routing decision or guidance incorporation/integration decision is required from the prioritisation board (go straight to prioritisation stage 2).

## **Omitting prioritisation stage 1**

- New topics formally notified directly from NHSE and DHSC
- Routing decision on technology appraisal or highly specialised technologies, as per the 2024 Department of Health and Social Care voluntary scheme for branded medicines, pricing, access and growth
- Updates of existing guidance that need ratification, a guidance incorporation or integration decision, or a routing decision.

## Not prioritised (other possible outcomes)

- Revisiting the topic or update later, for example, when more evidence or system intelligence becomes available
- Producing an alternative NICE product such as a quality standard or clinical knowledge summary
- Developing research recommendations
- Cross-referencing to suitable guidance or guideline recommendations produced by other organisations
- Engaging with external bodies to explore appropriate solutions (for example, the Royal Colleges, specialist societies, other armslength bodies, or NHSE)
- No further action
- Standing down content (for updates only).